Roberta Lenti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Roberta Lenti has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Annamaria De Luca
Department of Pharmacy-Drug Sciences, University of Bari “Aldo Moro”, 70125 Bari, Italy
2 shared publications Antonietta Mele
Section of Pharmacology, Department of Pharmacy—Drug Sciences University of Bari “Aldo Moro” Bari Italy
2 shared publications- Brigida Boccanegra
Department of Pharmacy – Drug Sciences, University of Bari “Aldo Moro”, Italy
2 shared publications Michela De Bellis
Section of Pharmacology, Department of Pharmacy—Drug Sciences University of Bari “Aldo Moro” Bari Italy
2 shared publications- Ornella Cappellari
Department of Pharmacy – Drug Sciences, University of Bari “Aldo Moro”, Italy
2 shared publications - Paola Mantuano
Department of Pharmacy – Drug Sciences, University of Bari “Aldo Moro”, Italy
2 shared publications
Latest Publications
- Open Access
- 22 April 2026
- Published by Wiley in British Journal of Pharmacology
- Vol. 183 (13) , 3866-3884
Diaphragm‐specific effects of L‐citrulline in mdx mice highlight its potential as adjuvant of standard therapy in Duchenne muscular dystrophy
Background and Purpose: The absence of the protein dystrophin in Duchenne muscular dystrophy (DMD) leads to progressive muscle weakness, failing regeneration and deregulation of nitric oxide (NO) signalling. We focused on L‐citrulline, a precursor of L‐arginine, required for NO production in muscle, which is reduced in dystrophic mdx muscle. Experimental Approach: L‐Citrulline was administered (2 mg g −1 die −1 ), through diet, in comparison and/or in combination with prednisolone (1 mg kg −1 , 5 days per week subcutaneously) to 4‐ to 5‐week‐old mdx mice for 8 weeks. Key Results: L‐Citrulline increased the levels of L‐arginine, L‐citrulline and L‐ornithine in plasma and quadriceps of mdx mice. L‐citrulline, alone or plus prednisolone, significantly improved maximal forelimb force in vivo, while ameliorating diaphragm movement amplitude and reducing diaphragm echodensity. In parallel, ex vivo, we detected a significant improvement of diaphragm force and contraction kinetics in mice treated with L‐citrulline alone or in combination with prednisolone. L‐citrulline also restored the expression of genes involved in Ca 2+ handling during contraction ( RyR1 , RyR3 and SERCA ), while reducing the markers of inflammation and fibrosis ( CD68 and TGFβ1 ) and ameliorating mitochondrial biogenesis‐associated genes ( PGC1‐α and MEF2C ). No effect was observed on S‐nitrosylation levels of HDAC2 and on diaphragm and gastrocnemius nNOS gene expression, suggesting a NO‐independent mechanism underlying the positive outcome observed. Conclusions: Our results revealed the ability of L‐citrulline supplementation to ameliorate in vivo and ex vivo function of diaphragm muscle, highlighting novel metabolic and calcium‐related mechanisms of potential clinical interest.
- 22 April 2026
- Published by Wiley in British Journal of Pharmacology
- Vol. 183 (13) , 3866-3884
Open AccessDiaphragm‐specific effects of L‐citrulline in mdx mice highlight its potential as adjuvant of standard therapy in Duchenne muscular dystrophy
Background and Purpose: The absence of the protein dystrophin in Duchenne muscular dystrophy (DMD) leads to progressive muscle weakness, failing regeneration and deregulation of nitric oxide (NO) signalling. We focused on L‐citrulline, a precursor of L‐arginine, required for NO production in muscle, which is reduced in dystrophic mdx muscle. Experimental Approach: L‐Citrulline was administered (2 mg g −1 die −1 ), through diet, in comparison and/or in combination with prednisolone (1 mg kg −1 , 5 days per week subcutaneously) to 4‐ to 5‐week‐old mdx mice for 8 weeks. Key Results: L‐Citrulline increased the levels of L‐arginine, L‐citrulline and L‐ornithine in plasma and quadriceps of mdx mice. L‐citrulline, alone or plus prednisolone, significantly improved maximal forelimb force in vivo, while ameliorating diaphragm movement amplitude and reducing diaphragm echodensity. In parallel, ex vivo, we detected a significant improvement of diaphragm force and contraction kinetics in mice treated with L‐citrulline alone or in combination with prednisolone. L‐citrulline also restored the expression of genes involved in Ca 2+ handling during contraction ( RyR1 , RyR3 and SERCA ), while reducing the markers of inflammation and fibrosis ( CD68 and TGFβ1 ) and ameliorating mitochondrial biogenesis‐associated genes ( PGC1‐α and MEF2C ). No effect was observed on S‐nitrosylation levels of HDAC2 and on diaphragm and gastrocnemius nNOS gene expression, suggesting a NO‐independent mechanism underlying the positive outcome observed. Conclusions: Our results revealed the ability of L‐citrulline supplementation to ameliorate in vivo and ex vivo function of diaphragm muscle, highlighting novel metabolic and calcium‐related mechanisms of potential clinical interest.
- Open Access
- 21 January 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (1) , 230
State-of-the-Art Research and New Pharmacological Perspectives on Renal Involvement in Duchenne Muscular Dystrophy: A Narrative Review
Background: Although Duchenne muscular dystrophy (DMD) is primarily characterized as a skeletal muscle-wasting disorder, the resulting pathophysiological changes extend to multiple non-muscle tissues and organ systems. Among these, renal and urinary tract dysfunctions have been reported, albeit in relatively few studies, as potential complications in DMD patients, sometimes occurring from an early age. Importantly, as life expectancy improves, the incidence of renal impairment is also expected to increase. This narrative review summarizes the available evidence on kidney involvement in DMD and discusses the associated biomarkers of renal dysfunction within the context of multisystem disease progression. Methods: The review draws on data from both human and animal studies and analyzes published evidence to explore kidney involvement in DMD, with a focus on clinical manifestations, biomarkers of renal dysfunction, and potential pathogenic mechanisms. Results: Available data indicate a close association between cardiac and renal dysfunction, particularly in patients with advanced-stage DMD. The review explores potential underlying mechanisms of renal impairment, including intrinsic dystrophin deficiency in the kidney, secondary effects of cardiovascular complications, and the nephrotoxic impact of drug therapies, highlighting renal function as an active determinant of clinical risk. Conclusions: While cardiac function monitoring is already a cornerstone of multidisciplinary care for this multisystem disease, systematic assessment of renal function should also be implemented, with implications for clinical management and drug safety. Moreover, the risk of drug-induced nephrotoxicity warrants attention in both clinical management and the development of novel therapeutic strategies for DMD.
- 21 January 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (1) , 230
Open AccessState-of-the-Art Research and New Pharmacological Perspectives on Renal Involvement in Duchenne Muscular Dystrophy: A Narrative Review
Background: Although Duchenne muscular dystrophy (DMD) is primarily characterized as a skeletal muscle-wasting disorder, the resulting pathophysiological changes extend to multiple non-muscle tissues and organ systems. Among these, renal and urinary tract dysfunctions have been reported, albeit in relatively few studies, as potential complications in DMD patients, sometimes occurring from an early age. Importantly, as life expectancy improves, the incidence of renal impairment is also expected to increase. This narrative review summarizes the available evidence on kidney involvement in DMD and discusses the associated biomarkers of renal dysfunction within the context of multisystem disease progression. Methods: The review draws on data from both human and animal studies and analyzes published evidence to explore kidney involvement in DMD, with a focus on clinical manifestations, biomarkers of renal dysfunction, and potential pathogenic mechanisms. Results: Available data indicate a close association between cardiac and renal dysfunction, particularly in patients with advanced-stage DMD. The review explores potential underlying mechanisms of renal impairment, including intrinsic dystrophin deficiency in the kidney, secondary effects of cardiovascular complications, and the nephrotoxic impact of drug therapies, highlighting renal function as an active determinant of clinical risk. Conclusions: While cardiac function monitoring is already a cornerstone of multidisciplinary care for this multisystem disease, systematic assessment of renal function should also be implemented, with implications for clinical management and drug safety. Moreover, the risk of drug-induced nephrotoxicity warrants attention in both clinical management and the development of novel therapeutic strategies for DMD.
- Open Access
- 13 November 2025
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 193, 118767
Novel insights into the effects of JMV2894, a growth hormone secretagogue, in Duchenne muscular dystrophy: A preclinical study in the D2-mdx mouse model
- 13 November 2025
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 193, 118767
Open AccessNovel insights into the effects of JMV2894, a growth hormone secretagogue, in Duchenne muscular dystrophy: A preclinical study in the D2-mdx mouse model